Bioequivalence assessment of Azomycin® (Julphar, UAE) as compared with Zithromax® (Pfizer, USA) - Two brands of Azithromycin - In healthy human volunteers

Biopharmaceutics and Drug Disposition

Volumn 22, Issue 1, 2001, Pages 15-21

  Najib, Naji M ^a   Idkaidek, Nasir ^b   Ghanemisra'Admour, Iz Eddein ^b   Alam, S Mahmood ^a   Zaman, Q ^a   Dham, Ruwayda ^a,b  

^a International Pharmaceutical Research Center Amman   (Jordan)

^b Gulf Pharmaceutical Industries   (United Arab Emirates)

Author keywords

Azithromycin; Bioequivalent study; HPLC; Pharmacokinetics

Indexed keywords

2 NITROIMIDAZOLE; AZITHROMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; STATISTICAL ANALYSIS; SUSPENSION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; CHEMISTRY, PHARMACEUTICAL; CONFIDENCE INTERVALS; HUMANS; MALE; NITROIMIDAZOLES; THERAPEUTIC EQUIVALENCY;

EID: 0035191031     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.252     Document Type: Article

References (25)

1. A distribution-free procedure for the statistical analysis of bioequivalence studies
2. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homo erythromycin A derivatives: A new class of macrolide antibiotics, the azalides
3. Pharmacokinetics of azithromycin in rats and dogs
4. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
5. The pharmacokinetics of azithromycin in human serum and tissues
6. Comparative in-vitro activity of azithromycin and erythromycin against gram-positive cocci, Haemophilus influenzae and anaerobes
7. Comparison of the acid stability of azithromycin and erythromycin A
8. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms
9. The new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin
10. Azithromycin-spectrum of activity, pharmacokinetics, and clinical applications
11. Tissue-directed pharmacokinetics
12. Clinical toleration and safety of azithromycin
13. Pharmacokinetics of azithromycin after single-and multiple-doses in children
14. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin
15. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: An open clinical, microbiological and pharmacokinetic study
16. Antimicrobials agents
17. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine
18. Bioequivalence Food and Drug Administration
19. Conference report: Analytical method validation: Bioavailability, bioequivalence and pharmacokinetic studies
20. A comparison of two one-sided tests procedure and the power approach for assessing the bioequivalence of average bioavailability
21. Pharmacokinetics of azithromycin in patients with impaired hepatic function
22. Azithromycin: A critical review of the first azilide antibiotic and its role in pediatric practice